Prevalence statistics for juvenile arthritis vary, but according to a 2008 report from the National Arthritis Data Workgroup, about 294,000 children age 0 to 17 are affected with arthritis or other rheumatic conditions.

Most forms of juvenile arthritis are autoimmune disorders, which means that the body’s immune system – which normally helps to fight off bacteria or viruses – mistakenly attacks some of its own healthy cells and tissues. The result is inflammation, marked by redness, heat, pain, and swelling. [1]

Developing new medicines to treat juvenile arthritis is a long and complex process, but an essential one in finding new and innovative treatments.

Join the Novartis clinical trials mailing list service to be notified of upcoming juvenile arthritis clinical trials.

[1] National Institute of Arthritis